The FDA has approved the New Drug Application for Triferic AVNU®.
Among those with baseline anemia, hemoglobin levels improved with canakinumab versus placebo.
In a study of kidney transplant recipients, mean hemoglobin levels rose from 10.69 g/dL prior to transplantation to 14.45 g/dL at 1 year after transplantation.
There is an especially urgent need for blood donors with type O blood and for platelet donors
A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.
Treatment with androgen deprivation therapy alone is associated with increased risks for anemia compared with radical prostatectomy alone, a study found.
Low hemoglobin levels are associated with a greater likelihood of kidney disease progression in patients with autosomal dominant polycystic kidney disease, a study found.
The FDA has accepted for review the New Drug Application (NDA) for roxadustat (FibroGen) for the treatment of anemia of chronic kidney disease (CKD) in both nondialysis-dependent and dialysis-dependent patients.
Hemoglobin levels greater than the current recommendations of 10.0 to 11.5 g/dL are associated with improved health-related quality of life among anemic patients with chronic kidney disease not on dialysis, a study found.
Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.